Innovative Therapeutic Pipeline Nuvig Therapeutics is focused on developing cutting-edge immunomodulatory therapies targeting autoimmune and inflammatory diseases, opening opportunities for partnerships in drug development, clinical trials, and supply chain integration for novel therapeutics.

Significant Funding & Growth With a recent $161 million Series B funding round led by major investors like Novo Holdings and Norwest Venture Partners, Nuvig demonstrates strong financial backing and growth potential, making it a compelling partner for companies offering research tools, clinical services, or partnership solutions.

Leadership & Strategic Expansion The appointment of new executive leadership and board members, including a Chief Medical Officer and Board Chair, indicates strategic expansion and maturity, creating opportunities for collaboration in medical research, regulatory consulting, and strategic advisory services.

Active Industry Engagement Participation in prominent industry events such as the Peripheral Nervous System Annual Meeting highlights Nuvig’s active engagement in research communities, providing avenues for technology providers, conference sponsors, and academic collaborations to engage with their R&D efforts.

Location & Market Focus Headquartered in Silicon Valley, Nuvig is well-positioned within a biotech innovation hub, facilitating connections with local service providers, biotech tools, and partnerships essential for advancing their research and product pipeline in the competitive immunology sector.